Serotonergic manipulations in experimental neoplastic spinal cord compression.
The effects of differing strategies of serotonergic manipulation on vascular permeability, prostaglandin E2 (PGE2) synthesis, and the clinical course are evaluated in an experimental model of neoplastic spinal cord compression in rats. Serotonergic manipulations include in vivo inhibition of serotonin (5-HT) synthesis by p-chlorophenylalanine (p-CPA) and in vivo blockage of serotonin type 2 (5-HT2) receptors either by the selective antagonist ketanserin or by cyproheptadine. In paralyzed rats, the ratio of 5-hydroxyindole-3-acetic acid (5-HIAA) to 5-HT is significantly elevated in the compressed segments, suggesting that 5-HT utilization is increased. Treatment with p-CPA attenuates spinal 5-HT levels by 62.8% +/- 5.1% (mean +/- standard deviation) and reduces the elevated 5-HIAA:5-HT ratio to the normal value. The increased synthesis of PGE2 observed in the compressed cord is unaffected by p-CPA or ketanserin treatment but is markedly attenuated by cyproheptadine. Ketanserin reduces the 10-fold increase in spinal cord permeability observed in paralyzed rats in a clearly dose-related manner. If given at the first sign of neurological dysfunction, ketanserin delays the onset of paraplegia with the 1-mg/kg dose being clearly superior. Cyproheptadine and p-CPA also reduce the increased permeability and protract the course to paraplegia. A comparison of the effect of dexamethasone, indomethacin, cyproheptadine, p-CPA, and ketanserin reveals that they protract the disease course by 48%, 57%, 60%, 64%, and 78%, respectively. These data suggest that 5-HT2 receptors mediate some of the deleterious vascular consequences observed in the compressed spinal cord by a mechanism not coupled with PGE2 synthesis. A potential benefit of serotonergic manipulations for the acute treatment of neoplastic spinal cord compression is suggested.
Siegal
T
T
Department of Neurology, Hadassah Hebrew University Hospital, Jerusalem, Israel.
Siegal
T
T
D000818:Animals; D002199:Capillary Permeability / Q000187:drug effects; D003533:Cyproheptadine / Q000494:pharmacology / Q000627:therapeutic use*; D003907:Dexamethasone / Q000494:pharmacology; D015232:Dinoprostone / Q000096:biosynthesis*; D004305:Dose-Response Relationship, Drug; D010134:Fenclonine / Q000627:therapeutic use*; D006897:Hydroxyindoleacetic Acid / Q000378:metabolism*; D007650:Ketanserin / Q000627:therapeutic use*; D051381:Rats; D011916:Rats, Inbred F344; D012701:Serotonin / Q000378:metabolism*; D012702:Serotonin Antagonists; D013116:Spinal Cord / Q000098:blood supply / Q000378:metabolism*; D013117:Spinal Cord Compression / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism
D012702:Serotonin Antagonists; D003533:Cyproheptadine; D012701:Serotonin; D006897:Hydroxyindoleacetic Acid; D003907:Dexamethasone; D007650:Ketanserin; D015232:Dinoprostone; D010134:Fenclonine